Literature DB >> 34822099

Biocatalytical Acyl-Modification of Puerarin: Shape Gut Microbiota Profile and Improve Short Chain Fatty Acids Production in Rats.

Lan Mo1, Guang-Lei Zhao2, Xiao-Feng Li3, Ning He4, Xing-Long Xiao1, Hai-Xia Xu1, Yi-Gang Yu5.   

Abstract

Gut microbiota balance and metabolites have become a potentially mechanism in maintaining health. The specific aim of this study was to compare the modulation of puerarin and puerarin acid esters on gut microbial composition and metabolites. Male mice were fed a control diet or diets supplemented with puerarin, puerarin propanoate ester, puerarin hexanoate ester, puerarin myristate ester for 24 h, respectively. The result revealed that puerarin acid esters with different chain lengths showed different activities to create more own impacted bacterial. Puerarin propanoate and puerarin hexanoate ester significantly improved the diversity of microbiota and promoted the relative abundance of beneficial gut microbiota such as Lactobacillus, Barnesiella, Clostridium IV, Prevotella. Additionally, the puerarin propanoate ester group showed the capacity to deliver specific propionic acid to the colon. But esters with medium-long chain lengths had more opportunity to alter gut microbiota for enhancing the short chain fatty acids production. As a whole, puerarin acid esters with different chain lengths supplements shaped different gut microbial and short chain fatty acids metabolism, which could improve human health.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Gut microbiota; Puerarin; Puerarin acid esters; Short chain fatty acids

Mesh:

Substances:

Year:  2021        PMID: 34822099     DOI: 10.1007/s11130-021-00936-1

Source DB:  PubMed          Journal:  Plant Foods Hum Nutr        ISSN: 0921-9668            Impact factor:   3.921


  1 in total

1.  Biopharmaceutics classification of puerarin and comparison of perfusion approaches in rats.

Authors:  Hewei Li; Ling Dong; Yang Liu; Guopeng Wang; Gang Wang; Yanjiang Qiao
Journal:  Int J Pharm       Date:  2014-03-05       Impact factor: 5.875

  1 in total
  1 in total

1.  Distinct alterations of fecal microbiota refer to the efficacy of adalimumab in Crohn's disease.

Authors:  Liang Chen; Zhanjun Lu; Dengfeng Kang; Zhongsheng Feng; Gengfeng Li; Mingming Sun; Zhanju Liu; Wei Wu; Leilei Fang
Journal:  Front Pharmacol       Date:  2022-08-11       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.